Information Provided By: 
Fly News Breaks for August 16, 2017
ENDP, TEVA, MYL
Aug 16, 2017 | 05:04 EDT
Citi analyst Liav Abraham upgraded Mylan (MYL) to Buy and raised her price target for the shares to $42 from $36. The company is best positioned to execute in a challenging operating environment for generics, Abraham tells investors in a research note. Mylan has a "differentiated and durable" generics product portfolio, "broad pipeline" of complex generics/ biosimilars and a more favorable balance sheet profile relative to peers, the analyst contends. She has Neutral ratings on Teva (TEVA) and Endo (ENDP).
News For MYL;TEVA;ENDP From the Last 2 Days
There are no results for your query MYL;TEVA;ENDP
